Blood test after taking palbociclib could predict response in advanced breast cancer

Research has shown that testing for  PIK3CA levels after taking palbociclib could help predict a progression-free survival, making it the first known biomarker for this therapy.
Source: Clinical Pharmacist - Category: Drugs & Pharmacology Source Type: research